- Главная
- Бесплатная аналитика приложений
- Pharmacist's Letter
- Pharmacist's Letter Vs. PneumoRecs VaxAdvisor
Pharmacist's Letter против PneumoRecs VaxAdvisor Использование & Stats
Get all the benefits of Pharmacist’s Letter, including CE, on the go. Pharmacist’s Letter from TRC Healthcare is vetted by clinicians to provide top-of-mind recommendations on the latest clinical findings in medication therapy.
Pharmacist's Letter includes:
• 12 issues every year, with concise, evidence-based recommendations about new medications and updated guidelines
• The largest CE library available to fulfill state-specific requirements, including new live and on-demand courses each month
• Clinical charts and other resources with actionable advice
- Apple App Store
- Бесплатный
- Медицина
Рейтинг магазина
- -
This is the PneumoRecs VaxAdvisor App created by the Centers for Disease Control and Prevention (CDC) in collaboration with the Georgia Tech Research Institute. PneumoRecs VaxAdvisor provides patient-specific pneumococcal vaccination guidance consistent with the pneumococcal vaccination recommendations of the Advisory Committee on Immunization Practices. Vaccination providers enter a patient’s age and respond to prompts about the patient’s pneumococcal vaccination history and underlying medical conditions. The app then displays patient-specific pneumococcal vaccination recommendations consistent with the recommended U.S. immunization schedule.
- Apple App Store
- Бесплатный
- Медицина
Рейтинг магазина
- -
Pharmacist's Letter vs. PneumoRecs VaxAdvisor ranking comparison
Compare Pharmacist's Letter ranking trend in the past 28 days vs. PneumoRecs VaxAdvisor
Rank
Нет данных
Рейтинг Pharmacist's Letter против PneumoRecs VaxAdvisor в сравнении по странам
Сравните динамику рейтинга Pharmacist's Letter за последние 28 дней с динамикой рейтинга PneumoRecs VaxAdvisor.
Все категории
Нет данных
Медицина
Сравните данные с любым сайтом, воспользовавшись бесплатной пробной версией
Pharmacist's Letter VS.
PneumoRecs VaxAdvisor
январь 3, 2025